Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Repayments (2016 - 2020)

Viridian Therapeutics, Inc.\DE has reported Long-Term Debt Repayments over the past 6 years, most recently at $9.0 million for Q4 2020.

  • Quarterly results put Long-Term Debt Repayments at $9.0 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Sep 2021 was $9.0 million (up 236.08% YoY), and the annual figure for FY2020 was $10.3 million, up 341.19%.
  • Long-Term Debt Repayments for Q4 2020 was $9.0 million at Viridian Therapeutics, Inc.\DE, up from $333000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for VRDN hit a ceiling of $9.0 million in Q4 2020 and a floor of $333000.0 in Q4 2016.
  • Median Long-Term Debt Repayments over the past 4 years was $500000.0 (2017), compared with a mean of $1.7 million.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 1565.0% in 2016 and later changed 0.0% in 2020.
  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Repayments stood at $333000.0 in 2016, then surged by 851.05% to $3.2 million in 2017, then crashed by 57.91% to $1.3 million in 2019, then skyrocketed by 572.17% to $9.0 million in 2020.
  • The last three reported values for Long-Term Debt Repayments were $9.0 million (Q4 2020), $333000.0 (Q2 2020), and $1.0 million (Q1 2020) per Business Quant data.